Key result
Redosing of adeno-associated virus gene therapy to the central nervous system requires continued study of immune responses and immunosuppressive regimens to allow for eventual use in patients.
Why the study?
Redosing AAV to the central nervous system is an important area of study given the immunological status of the CNS and potential loss of glial transgene expression over time after a single injection.
Continued study of immune responses and immunosuppressive regimens could allow for eventual redosing of AAV gene therapies in the CNS.
Answers are grounded in this paper and cite their sources.
Redosing AAV gene therapy in the CNS remains investigational; leaves open optimized immunosuppression strategies for future clinical translation.
Adeno-associated virus (AAV)-mediated gene therapies have provided promising treatments for numerous neurological disorders. Redosing of AAV to the central nervous system (CNS) is an attractive research area due to both the somewhat immunologically privileged status of the CNS as well as the possibility of reduced glial transgene expression over time following a single injection. Continued study of the immune responses to both intraparenchymal and intra-CSF delivery of AAV mediated gene therapies, as well as the continued study of immunosuppressive regimens, could allow for eventual redosing in patients.
No takes yet. Share an insight, caveat, or question.
McElroy et al. (2022) conducted a review in Neurological disorders. Redosing Adeno-Associated Virus (AAV) Gene Therapy was evaluated. Redosing of adeno-associated virus gene therapy to the central nervous system requires continued study of immune responses and immunosuppressive regimens to allow for eventual use in patients.
Synapse has enriched 10 related papers. Consider them for comparative context: